Skip to Main Content
Table III.

Effects of a Specific iNOS Inhibitor on the Development of DSS Colitis




Colonlength

Histology

MPOactivity
  cm score U/g colon 
WT saline plus DSS 5.1 ± 0.31 19.8 ± 1.7 21.1 ± 1.5 
WT 1400W plus DSS 6.6 ± 0.3a 10.8 ± 1.4a 10.6 ± 2.8a 
p47phox−/− saline plus DSS 5.0 ± 0.1 19.2 ± 3.4 20.3 ± 2.5 
p47phox−/− 1400W plus DSS 7.9 ± 0.2b,c 1.8 ± 0.8b,c 5.2 ± 1.7c 
WT plus DSS 4.8 ± 0.2 17.9 ± 0.7 19.0 ± 2.5 
iNOS−/−
 
plus DSS
 
5.9 ± 0.2d
 
12.0 ± 1.5d
 
9.9 ± 2.0d
 



Colonlength

Histology

MPOactivity
  cm score U/g colon 
WT saline plus DSS 5.1 ± 0.31 19.8 ± 1.7 21.1 ± 1.5 
WT 1400W plus DSS 6.6 ± 0.3a 10.8 ± 1.4a 10.6 ± 2.8a 
p47phox−/− saline plus DSS 5.0 ± 0.1 19.2 ± 3.4 20.3 ± 2.5 
p47phox−/− 1400W plus DSS 7.9 ± 0.2b,c 1.8 ± 0.8b,c 5.2 ± 1.7c 
WT plus DSS 4.8 ± 0.2 17.9 ± 0.7 19.0 ± 2.5 
iNOS−/−
 
plus DSS
 
5.9 ± 0.2d
 
12.0 ± 1.5d
 
9.9 ± 2.0d
 
a

P < 0.05 vs. WT saline plus DSS.

b

P < 0.05 vs. WT 1400W plus DSS.

c

P < 0.05 vs. p47phox−/− saline plus DSS.

d

P < 0.05 vs. WT plus DSS.

Effects of treatment with 1400W on susceptibility to DSS-induced colitis in WT and p47phox−/− mice (n = 5/group). 1400W (or saline in controls) was administered over 7 d using a subcutaneously implanted miniosmotic pump parallel to feeding DSS in drinking water. To facilitate how the iNOS−/− compound compared in relation to 1400W-treated mice the result of DSS administration to iNOS−/− mice and their appropriate controls is shown as a subsection of this table.

Close Modal

or Create an Account

Close Modal
Close Modal